- Home
- CBUS
CBUS
Cibus Inc.
as 02-21-2025 12:33pm EST
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 120.1M | IPO Year: | 2017 |
| Target Price: | $22.17 | AVG Volume (30 days): | 128.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -21.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.11 - $23.18 | Next Earning Date: | 03-20-2025 |
| Revenue: | $4,152,999 | Revenue Growth: | 449.34% |
| Revenue Growth (this year): | 132.42% | Revenue Growth (next year): | 97.96% |
Stock Insider Trading Activity of Cibus Inc. (CBUS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Prante Gerhard | CBUS | Director | Feb 14 '25 | Sell | $2.60 | 1,150 | $2,990.00 | 15,757 | |
| Prante Gerhard | CBUS | Director | Feb 13 '25 | Sell | $2.53 | 1,150 | $2,909.50 | 15,757 | |
| Prante Gerhard | CBUS | Director | Feb 12 '25 | Sell | $2.45 | 1,150 | $2,817.50 | 15,757 | |
| Prante Gerhard | CBUS | Director | Feb 11 '25 | Sell | $2.48 | 1,150 | $2,852.00 | 15,757 | |
| Prante Gerhard | CBUS | Director | Feb 6 '25 | Sell | $2.55 | 1,150 | $2,932.50 | 15,757 | |
| Prante Gerhard | CBUS | Director | Feb 5 '25 | Sell | $2.52 | 1,150 | $2,898.00 | 15,757 | |
| Prante Gerhard | CBUS | Director | Feb 4 '25 | Sell | $2.45 | 1,150 | $2,817.50 | 15,757 | |
| Prante Gerhard | CBUS | Director | Feb 3 '25 | Sell | $2.41 | 1,150 | $2,771.50 | 15,757 | |
| Prante Gerhard | CBUS | Director | Jan 31 '25 | Sell | $2.55 | 1,150 | $2,932.50 | 15,757 | |
| Prante Gerhard | CBUS | Director | Jan 30 '25 | Sell | $2.46 | 1,150 | $2,829.00 | 15,757 |
Latest Cibus Inc. News
CBUS Breaking Stock News: Dive into CBUS Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Cibus Announces Important Update to Rice Gene Editing Conversion Rates
GlobeNewswire
24 days ago
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
GlobeNewswire
a month ago
Cibus to Participate in the Sidoti Micro Cap Conference
ACCESS Newswire
a month ago
Sidoti Events, LLC's Virtual January Micro-Cap Conference
GlobeNewswire
a month ago
Cibus, Inc. Announces $22.6 Million Registered Direct Offering Priced Above Nasdaq’s Minimum Price in Accordance with Nasdaq Rules
GlobeNewswire
a month ago
Cibus’ Agriculture Breeding Breakthroughs Create New Industry Paradigms for Development and Commercialization of Plant Traits
TipRanks
2 months ago
Cibus, Albaugh, RTDC affirm collaboration for weed management solution
GlobeNewswire
2 months ago
Cibus, Albaugh LLC and RTDC Company Limited Affirm Collaboration to Enable Commercialization of Cibus’ First Gene Edited Weed Management Solution for U.S. Rice Growers
Compare CBUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CBUS Cibus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.